期刊
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
卷 16, 期 1, 页码 51-59出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.ijir.3901139
关键词
erectile dysfunction; melanocortin; PT-141
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScant(TM) in healthy subjects without visual sexual stimulation (VSS) and in Viagra(R)-responsive ED patients with VSS. In healthy subjects, mean C-max and AUC((0-t)) increased in a dose-dependent manner. Median T-max was 0.50 h and mean t(1/2) ranged from 1.85 to 2.09 h. In both studies, an erectile response induced by PT-141 administration was statistically significant, compared to placebo, at doses greater than 7 mg, with the onset of the first erection occurring in approximately 30 min. PT-141 was safely administered and well tolerated in both studies. A maximum-tolerated dose was not identified. Flushing and nausea were the most common adverse events reported in both studies and no clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed. Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据